Pseudoviral Assay for SARS-CoV-2 Spike Protein Screening
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for effective treatment methods and therapeutic agents to modulate and reduce symptoms of viral infections such as those caused by SARS-CoV-2, as well as for methods to assay the efficacy of potential therapeutic agents for coronavirus infections.
Innovation Solution
The method involves expressing angiotensin-converting enzyme 2 (ACE-2) and/or nicotinic acetylcholine receptor (nAChR) receptors on target cells, contacting them with SARS-CoV-2 spike protein-containing viral particles in the presence and absence of a compound, and measuring infection levels to determine the compound's modulating effect on viral infectivity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If compounds are tested for modulation of coronavirus infection using traditional methods, then the assessment of therapeutic efficacy is limited, but the development of effective treatment methods is needed
Solution Approach 1:
The patent performs preliminary actions by expressing ACE-2 and nAChR receptors on target cells before viral infection, and by pre-testing compounds against pseudoviral particles containing SARS-CoV-2 spike protein. This preliminary setup enables efficient screening and assessment of therapeutic compounds' ability to block viral entry, thereby accelerating treatment development while maintaining reliable efficacy assessment.
Solution Approach 2:
The patent uses pseudoviral particles containing SARS-CoV-2 spike protein as an intermediary system to test compound efficacy. These pseudoviruses serve as safe mediators that allow researchers to assess therapeutic compounds' ability to block viral entry without handling live SARS-CoV-2, thus improving both safety and assessment reliability while accelerating development.
2Manufacturing precision
If the spike protein structure is utilized for drug design, then the precision of therapeutic agent development is improved, but the complexity of identifying effective compounds increases
Solution Approach 1:
The patent segments the complex spike protein structure into functional domains (S1 subunit for ACE-2 binding, S2 subunit for membrane fusion) and tests compounds against specific functional outcomes (viral entry blockade). This segmentation approach maintains precision in understanding protein-function relationships while simplifying the identification process by focusing on specific binding interactions rather than the entire complex structure.
Solution Approach 2:
The patent creates simplified copies of the viral entry system using pseudoviral particles that contain only the essential SARS-CoV-2 spike protein components needed for entry. This copying approach maintains the precision of studying spike protein-mediated entry while reducing the complexity of working with complete, live viral systems, thereby facilitating compound identification.
3Measurement precision
If ACE-2 and nAChR receptors are expressed on target cells for infection assays, then the accuracy of infectivity measurement is improved, but the complexity of the assay system increases
Solution Approach 1:
The patent merges the expression of multiple receptors (ACE-2 and nAChR) into a single target cell line, allowing simultaneous testing of compounds against multiple viral entry pathways. This merging approach maintains measurement precision by preserving natural co-receptor interactions while reducing assay complexity compared to using separate cell lines for each receptor.
Solution Approach 2:
The patent creates a universal target cell system that can simultaneously assess compounds against multiple viral entry mechanisms (ACE-2-mediated and nAChR-mediated). This multi-functional cell system improves measurement accuracy by capturing the full spectrum of viral entry pathways while simplifying the overall assay design compared to conducting separate assays for each receptor type.
Data Source
AI summary
The present disclosure relates to methods, compositions and systems for modulation of a coronavirus (e.g., SARS CoV-2) and/or the evaluation of compounds that can modulate infectivity of the coronavirus. For example, disclosed is a method to identify a compound that can modulate infection by the coronavirus comprising the steps of: expressing an angiotensin-converting enzyme 2 receptor (ACE-2) and/or a nicotinic acetylcholine receptor (nAChR) receptor on a target cell; contacting the target cell with a viral particle comprising at least a portion of the coronavirus spike protein in the absence and the presence of the compound; and measuring levels of infection of the target cell in order to determine infectivity of the viral particle in the presence or absence of the compound. Also, disclosed are compounds and methods of treatment identified using the methods, compositions, and systems.